Invivyd
Update in progressIVVD (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Invivyd, Inc. and its subsidiaries develop and commercialize antibody therapies to prevent and treat viral infections in the United States. Pemivibart, a long-acting monoclonal antibody for COVID-19 pre-exposure prophylaxis, is sold under PEMGARDA. VYD2311 is in Phase III for SARS-CoV-2; VBY329 is preclinical for RSV and measles in children. The company collaborates with Adimab for antibody discovery. Formerly Adagio Therapeutics, renamed Invivyd in 2022. Based in New Haven, CT, founded in 2020.
Company score
- Sentiment
- 0.33
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section